Specifically targeting interleukin-13 with tralokinumab improved sleep in two phase III, randomized, double-blind, placebo-controlled trials in patients with atopic dermatitis

被引：0
|
作者：
Silverberg, J. I. [1 ]
Barbarot, S. [2 ]
Gooderham, M. [3 ]
Simon, J. C. [4 ]
Simpson, E. [5 ]
Kurbasic, A. [6 ]
Olsen, C. K. [6 ]
Cork, M. J. [7 ]
机构：
[1] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC 20052 USA
[2] CHU Nantes, Dept Dermatol, Nantes, France
[3] SKiN Ctr Dermatol, Peterborough, ON, Canada
[4] Univ Med Ctr, Dept Dermatol Venereol & Allergol, Leipzig, Germany
[5] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[6] LEO Pharma AS, Ballerup, Denmark
[7] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Sheffield Dermatol Res, Sheffield, S Yorkshire, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 184卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
342
引用
收藏
页码：E64 / E65
页数：2
相关论文
共 50 条
  • [1] The targeted Action on Interleukin-13 with Tralokinumab improved the Sleep in two randomized, double-blind, placebo-controlled Phase III Studies in Patients with atopic Dermatitis
    Simon, J. C.
    Barbarot, S.
    Gooderham, M.
    Simpson, E.
    Kurbasic, A.
    Olsen, C. K.
    Cork, M. J.
    Silverberg, J., I
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 56 - 56
  • [2] Safety of specifically targeting interleukin-13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase III and phase II trials
    Simpson, E.
    Merola, J. F.
    Silverberg, J. I.
    Zachariae, R.
    Olsen, C. K.
    Wollenberg, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E66 - E66
  • [3] Impact of targeting interleukin-13 on Staphylococcus aureus colonization: results from a phase III, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis
    Bieber, T.
    Beck, L. A.
    Pink, A.
    Saeki, H.
    Eichenfield, L.
    Werfel, T.
    Rosholm, A.
    Roepke, M.
    Paller, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E112 - E112
  • [4] Neutralization of Interleukin-13 increases Skin microbial Diversity: Results of a randomized, double-blind, placebo-controlled Phase III Trial of Tralokinumab in adult Patients with Atopic Dermatitis
    Bieber, Thomas
    Beck, Lisa A.
    Pink, Andrew
    Saeki, Hidehisa
    Eichenfield, Lawrence
    Werfel, Thomas
    Ropke, Mads
    Paller, Amy
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 18 - 18
  • [5] Neutralizing interleukin-13 increases skin microbial diversity: results from a phase III, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis
    Bieber, T.
    Beck, L. A.
    Pink, A.
    Saeki, H.
    Eichenfield, L.
    Werfel, T.
    Rosholm, A.
    Ropke, M.
    Paller, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E111 - E112
  • [6] Influence of Targeting of Interleukin-13 on Colonization with Staphylococcus aureus: Results of a randomized, double-blind, placebo controlled Phase III Study with Tralokinumab in Adult Patients with Atopical Dermatitis
    Bieber, T.
    Beck, L. A.
    Pink, A.
    Saeki, H.
    Eichenfield, L.
    Rosholm, A.
    Roepke, M.
    Paller, A.
    Werfel, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 66 - 67
  • [7] Neutralizing interleukin-13 increases skin microbial diversity: Results from a phase 3, randomized, double-blind, placebo-controlled trial with tralokinumab in adult patients with atopic dermatitis
    Bieber, Thomas
    Beck, Lisa A.
    Pink, Andrew
    Saeki, Hidehisa
    Eichenfield, Lawrence
    Werfel, Thomas
    Rosholm, Anders
    Ropke, Mads
    Paller, Amy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB177 - AB177
  • [8] Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
    Simpson, Eric L.
    Merola, Joseph F.
    Silverberg, Jonathan, I
    Reich, Kristian
    Warren, Richard B.
    Staumont-Salle, Delphine
    Girolomoni, Giampiero
    Papp, Kim
    de Bruin-Weller, Marjolein
    Thyssen, Jacob P.
    Zachariae, Rebecca
    Olsen, Christiana K.
    Wollenberg, Andreas
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 888 - 899
  • [9] Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)
    Wollenberg, A.
    Blauvelt, A.
    Guttman-Yassky, E.
    Worm, M.
    Lynde, C.
    Lacour, J. -P.
    Spelman, L.
    Katoh, N.
    Saeki, H.
    Poulin, Y.
    Lesiak, A.
    Kircik, L.
    Cho, S. H.
    Herranz, P.
    Cork, M. J.
    Peris, K.
    Steffensen, L. A.
    Bang, B.
    Kuznetsova, A.
    Jensen, T. N.
    osterdal, M. L.
    Simpson, E. L.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 437 - 449
  • [10] A new treatment for atopic dermatitis: a randomized double-blind placebo-controlled study
    Freeman, S
    Day, R
    Williams, K
    Liauw, W
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB3 - AB3
12345